Hubei Minkang Pharmaceutical Group Co., Ltd.

Main purpose: Using the licensee Anacor Pharmaceuticals, Inc.'s crisaborole ointment (2%, trade name Staquis) as the reference preparation and the Hubei Minkang Pharmaceutical Group Co., Ltd.'s crisaborole ointment (2%) as the test preparation, a single-center, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, crossover clinical trial was conducted to evaluate the bioequivalence of the two preparations under topical conditions in Chinese healthy subjects. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) To evaluate the skin reactivity of the test preparation and the reference preparation in Chinese healthy subjects.

Main purpose: Using the nalfuraphine hydrochloride orally disintegrating tablets (trade name: Remitch OD Tablets, specification: 2.5 μg) of Tori Co., Ltd. as the reference preparation, and using the drug developed by Hubei Minkang Pharmaceutical Group Co., Ltd. Nafuraphine hydrochloride orally disintegrating tablets are the test preparations. A single-center, randomized, open-label, single-dose, two-preparation, two-cycle, two-sequence, crossover design clinical trial was conducted to evaluate the two preparations in healthy subjects in China. Bioequivalence in fasted and postprandial states. Secondary purpose: To observe the safety of the test preparation and reference preparation in Chinese healthy subjects.

Main purpose: Using lidocaine gel patch (5%, trade name Lidoderm®) from TEIKOKU PHARMA USA INC as reference preparation and lidocaine gel patch developed by Hubei Minkang Pharmaceutical Group Co., Ltd. [14g of paste per patch (14.0cm×10.0cm), 700mg of lidocaine (C14H22N2O) per patch] as test preparation, the bioequivalence of the two preparations under topical conditions in Chinese healthy subjects was evaluated through a single-center, randomized, open, single-dose, two-preparation, two-period, four-sequence, crossover design clinical trial. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) To evaluate the adhesion of the test preparation and the reference preparation during medication in Chinese healthy subjects; 3) To evaluate the skin reactivity of the test preparation and the reference preparation in Chinese healthy subjects.